Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
|Articles|March 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 3
- Volume 15
- Issue 3
Zactima Gets Fast Track Status for Medullary Thyroid Cancer
AstraZeneca, Zactima, ZD6474, medullary thyroid cancer
Advertisement
WILMINGTON, DelawareAstraZeneca's Zactima (ZD6474) has received FDA fast track designation for the treatment of medullary thyroid cancer. Zactima, a once-daily oral agent, targets tumor cells through inhibition of EGFR and REarranged during Transfection (RET) tyrosine kinases, and tumor blood supply through inhibition of VEGFR tyrosine kinase. Zactima, which also has orphan drug status for medullary thyroid cancer, is currently being evaluated in a phase II clinical trial.
Articles in this issue
over 20 years ago
FDA Approves Eraxis to Treat Candidemiaover 20 years ago
NeoGuide's New Colonoscopy System Addresses ‘Looping'over 20 years ago
New Budget Plan Cuts NCI Funding by 0.8% for FY 2007over 20 years ago
Lilly Oncology on Canvas Invites Entriesover 20 years ago
Shorter FEC + Pac Ups DFS in Breast Caover 20 years ago
Xyotax Fast Tracked for Advanced NSCLC in Womenover 20 years ago
FDA Guidances for Early Human Testing of New Drugsover 20 years ago
Darbepoetin During RT Boosts Hb Level, With QOL Benefitover 20 years ago
Breast, Colorectal Cancer Care Quality 'Excellent'over 20 years ago
Dose-Dense Adjuvant Chemo Validated in Breast CancerAdvertisement
Related to this article
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5